4.7 Meeting Abstract

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 15, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2021.39.15_suppl.7552

Keywords

-

Categories

Funding

  1. U.S. National Institutes of Health Pharmaceutical/Biotech Company

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available